Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 125500.0
(-2.64%)
KRW 125500.0
(-2.64%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 681.55 Billion KRW | 6.67% |
| 2022 | 638.95 Billion KRW | 17.29% |
| 2021 | 544.74 Billion KRW | 21.88% |
| 2020 | 446.94 Billion KRW | -6.55% |
| 2019 | 478.29 Billion KRW | 16.67% |
| 2018 | 409.94 Billion KRW | 0.73% |
| 2017 | 406.98 Billion KRW | 8.91% |
| 2016 | 373.68 Billion KRW | 23.49% |
| 2015 | 302.6 Billion KRW | 12.0% |
| 2014 | 270.18 Billion KRW | -7.38% |
| 2013 | 291.7 Billion KRW | 5.26% |
| 2012 | 277.11 Billion KRW | -7.85% |
| 2011 | 300.71 Billion KRW | 33.98% |
| 2010 | 224.45 Billion KRW | -23.06% |
| 2009 | 291.71 Billion KRW | 14.85% |
| 2008 | 254 Billion KRW | -2.45% |
| 2007 | 260.38 Billion KRW | 17.89% |
| 2006 | 220.87 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 168.51 Billion KRW | -6.1% |
| 2024 Q2 | 188.66 Billion KRW | 11.96% |
| 2023 FY | 681.55 Billion KRW | 6.67% |
| 2023 Q1 | 158.98 Billion KRW | -2.87% |
| 2023 Q4 | 179.45 Billion KRW | 8.84% |
| 2023 Q3 | 164.87 Billion KRW | -9.96% |
| 2023 Q2 | 183.11 Billion KRW | 15.18% |
| 2022 Q3 | 168.58 Billion KRW | 3.35% |
| 2022 Q4 | 163.68 Billion KRW | -2.91% |
| 2022 FY | 638.95 Billion KRW | 17.29% |
| 2022 Q2 | 163.11 Billion KRW | 13.61% |
| 2022 Q1 | 143.57 Billion KRW | -0.81% |
| 2021 Q3 | 134.67 Billion KRW | -1.42% |
| 2021 Q1 | 128.71 Billion KRW | 9.51% |
| 2021 Q2 | 136.61 Billion KRW | 6.14% |
| 2021 Q4 | 144.74 Billion KRW | 7.48% |
| 2021 FY | 544.74 Billion KRW | 21.88% |
| 2020 Q4 | 117.53 Billion KRW | 7.03% |
| 2020 Q1 | 112.5 Billion KRW | -3.76% |
| 2020 FY | 446.94 Billion KRW | -6.55% |
| 2020 Q3 | 109.81 Billion KRW | 2.56% |
| 2020 Q2 | 107.07 Billion KRW | -4.82% |
| 2019 FY | 478.29 Billion KRW | 16.67% |
| 2019 Q1 | 111.43 Billion KRW | 2.84% |
| 2019 Q3 | 119.7 Billion KRW | -8.1% |
| 2019 Q4 | 116.9 Billion KRW | -2.34% |
| 2019 Q2 | 130.24 Billion KRW | 16.88% |
| 2018 Q3 | 101.05 Billion KRW | -2.66% |
| 2018 FY | 409.94 Billion KRW | 0.73% |
| 2018 Q1 | 96.71 Billion KRW | -4.69% |
| 2018 Q2 | 103.81 Billion KRW | 7.34% |
| 2018 Q4 | 108.36 Billion KRW | 7.23% |
| 2017 Q1 | 92.91 Billion KRW | -4.1% |
| 2017 FY | 406.98 Billion KRW | 8.91% |
| 2017 Q4 | 101.47 Billion KRW | -7.09% |
| 2017 Q3 | 109.21 Billion KRW | 5.64% |
| 2017 Q2 | 103.38 Billion KRW | 11.27% |
| 2016 FY | 373.68 Billion KRW | 23.49% |
| 2016 Q1 | 88.48 Billion KRW | 1.48% |
| 2016 Q4 | 96.87 Billion KRW | 3.84% |
| 2016 Q3 | 93.29 Billion KRW | -1.83% |
| 2016 Q2 | 95.03 Billion KRW | 7.4% |
| 2015 FY | 302.6 Billion KRW | 12.0% |
| 2015 Q1 | 68.7 Billion KRW | 9.65% |
| 2015 Q2 | 70.92 Billion KRW | 3.23% |
| 2015 Q3 | 75.77 Billion KRW | 6.84% |
| 2015 Q4 | 87.19 Billion KRW | 15.07% |
| 2014 Q1 | 65.79 Billion KRW | 0.61% |
| 2014 FY | 270.18 Billion KRW | -7.38% |
| 2014 Q3 | 71.51 Billion KRW | 1.86% |
| 2014 Q4 | 62.66 Billion KRW | -12.38% |
| 2014 Q2 | 70.21 Billion KRW | 6.71% |
| 2013 Q2 | 74.5 Billion KRW | 1.1% |
| 2013 Q1 | 73.7 Billion KRW | 8.72% |
| 2013 FY | 291.7 Billion KRW | 5.26% |
| 2013 Q4 | 65.4 Billion KRW | -16.32% |
| 2013 Q3 | 78.16 Billion KRW | 4.9% |
| 2012 FY | 277.11 Billion KRW | -7.85% |
| 2012 Q1 | 71.14 Billion KRW | 0.0% |
| 2012 Q2 | 63.24 Billion KRW | -11.1% |
| 2012 Q3 | 73.99 Billion KRW | 17.01% |
| 2012 Q4 | 67.79 Billion KRW | -8.39% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 300.71 Billion KRW | 33.98% |
| 2011 Q3 | 79.91 Billion KRW | 2.01% |
| 2011 Q2 | 78.34 Billion KRW | 6.78% |
| 2011 Q1 | 73.37 Billion KRW | 0.0% |
| 2010 Q2 | 77.43 Billion KRW | 2.92% |
| 2010 FY | 224.45 Billion KRW | -23.06% |
| 2010 Q3 | 73.74 Billion KRW | -4.77% |
| 2010 Q1 | 75.24 Billion KRW | 2.89% |
| 2009 Q4 | 73.12 Billion KRW | -1.59% |
| 2009 FY | 291.71 Billion KRW | 14.85% |
| 2009 Q3 | 74.31 Billion KRW | 7.65% |
| 2009 Q2 | 69.03 Billion KRW | 0.0% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 FY | 254 Billion KRW | -2.45% |
| 2008 Q3 | 66.67 Billion KRW | 1.4% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 Q2 | 65.75 Billion KRW | 0.0% |
| 2008 Q4 | 63.09 Billion KRW | -5.36% |
| 2007 Q2 | 59.68 Billion KRW | 0.0% |
| 2007 FY | 260.38 Billion KRW | 17.89% |
| 2007 Q4 | 69.04 Billion KRW | 3.59% |
| 2007 Q3 | 66.64 Billion KRW | 11.66% |
| 2006 FY | 220.87 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -1365.538% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | -87.183% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -242.682% |
| HANDOK Inc. | 151.36 Billion KRW | -350.264% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -913.84% |
| Yuhan Corporation | 564.5 Billion KRW | -20.733% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | -111.522% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -2770.036% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 18.461% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -808.254% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -242.553% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -1576.645% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -621.098% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -383.863% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -1365.538% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -1863.226% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -787.222% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 5758.073% |
| JW Holdings Corporation | 446.15 Billion KRW | -52.76% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | -228.396% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | -3.999% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -103.04% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -766.893% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -805.858% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -843.823% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -270.781% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -1365.538% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | -130.941% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -103.04% |
| Yuhan Corporation | 564.5 Billion KRW | -20.733% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | -237.699% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -860.753% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -588.246% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -103.04% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -367.162% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -292.851% |
| CKD Bio Corp. | 5.01 Billion KRW | -13502.963% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | -168.082% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -270.157% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -594.57% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -766.893% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | -83.46% |
| Boryung Corporation | 333.26 Billion KRW | -104.504% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -1261.859% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -242.553% |
| JW Lifescience Corporation | 51.32 Billion KRW | -1227.91% |